Shukra Pharmaceuticals to change name to Shukra Medtech Limited; AGM on Sep 25
Shukra Pharmaceuticals Limited approved changing its name to Shukra Medtech Limited, subject to approvals. The company will alter its MOA to reflect the new focus. The 33rd AGM is scheduled for September 25, 2026, with the Register of Members closed from September 19-25.
The name change and alteration of MOA are significant strategic decisions that could lead to future growth and diversification. However, the immediate impact depends on the successful execution of these changes and market reception. The AGM and closure of the register are routine corporate actions.
The name change to 'Shukra Medtech Limited' and alteration of MOA indicate a strategic shift and potential expansion into a new, possibly more lucrative, sector (Medtech), which is generally viewed positively by investors.
Shukra Pharmaceuticals Limited has announced a significant change in its corporate identity and business focus following a Board of Directors meeting held on August 22, 2026. The company has approved a proposal to change its name from 'Shukra Pharmaceuticals Limited' to 'Shukra Medtech Limited'. This change is subject to shareholder and relevant regulatory body approvals.
The Board also recommended an alteration in the main objects of the Company's Memorandum of Association (MOA) to reflect the new business direction, which will require shareholder approval through a postal ballot.
Further, the company has scheduled its 33rd Annual General Meeting (AGM) for September 25, 2026, at 12:00 PM IST. The meeting will be conducted via Video Conferencing (VC). To facilitate the AGM, the Register of Members & Share Transfer Books will remain closed from September 19, 2026, to September 25, 2026, inclusive. CS Rupal Patel has been appointed as the Scrutinizer for the e-voting process and the AGM voting.
The Board also approved the Director's Report and the Secretarial Audit Report for the year ended March 31, 2026.
What to do with a filing like this
Shukra Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under other corporate actions. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Shukra Pharmaceuticals Limited. Read the original for the full detail.